Back to search results

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Abroad (travel likely)RecruitingPHASE1

Conditions

Systemic Lupus Erythematosus (SLE) · Immune-mediated Necrotizing Myopathy (IMNM) · Neuromyelitis Optica Spectrum Disorders (NMOSD) · Multiple Sclerosis (MS) · Myasthenia Gravis · Systemic Sclerosis (SSc)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, Shanghai Municipality, China

    Contact: Study coordinator (Nan Shen, MD & PhD) · nanshensibs@gmail.com · +86-21-63260477
    Contact: Study coordinator (Huihua Ding, MD) · dinghuihua@outlook.com · +86-21-53882280
    Contact: Principal Investigator (Nan Shen, MD & PhD)
    Contact: Principal Investigator (Huihua Ding, MD)
Study leads

  • Nan Shen, MD & PhD

    Principal Investigator

    Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University

View source on ClinicalTrials.gov(opens in a new tab)